- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BIODLINK-B (01875): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 3 | HKEx | ||
| Di | BIODLINK-B (01875): (1) RESIGNATION OF DIRECTORS AND CHAIRPERSON OF THE BOARD; (2) APPOINTMENTS OF DIRECTORS, CHAIRPERSON OF THE BOARD AND CHANGES IN ... | - | HKEx | ||
| Di | BIODLINK-B (01875): ANNUAL REPORT 2025 | 2 | HKEx | ||
| BIODLINK INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 31.03. | BIODLINK-B (01875): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ... | - | HKEx | ||
| 18.03. | BIODLINK-B (01875): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 13.03. | BIODLINK-B (01875): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ... | 1 | HKEx | ||
| 05.03. | BIODLINK-B (01875): DATE OF BOARD MEETING | 1 | HKEx | ||
| 03.03. | BIODLINK-B (01875): CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 03.03. | BIODLINK-B (01875): CLARIFICATION ANNOUNCEMENT IN RELATION TO THE ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE | - | HKEx | ||
| 11.02. | BIODLINK-B (01875): JOINT ANNOUNCEMENT DESPATCH OF COMPOSITE DOCUMENT RELATING TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED ... | 1 | HKEx | ||
| 11.02. | BIODLINK-B (01875): WHITE FORM OF SHARE OFFER ACCEPTANCE AND TRANSFER OF ORDINARY SHARE(S) IN THE ISSUED SHARE CAPITAL OF BIODLINK INTERNATIONAL COMPANY ... | 2 | HKEx | ||
| 11.02. | BIODLINK-B (01875): PINK FORM OF OPTION OFFER ACCEPTANCE AND CANCELLATION OF SHARE OPTIONS GRANTED BY BIODLINK INTERNATIONAL COMPANY LIMITED | 2 | HKEx | ||
| 11.02. | BIODLINK-B (01875): COMPOSITE OFFER AND RESPONSE DOCUMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF ... | 1 | HKEx | ||
| 04.02. | BIODLINK-B (01875): JOINT ANNOUNCEMENT DELAY IN DESPATCH OF COMPOSITE DOCUMENT RELATING TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ... | 2 | HKEx | ||
| 19.01. | BIODLINK-B (01875): APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER | 1 | HKEx | ||
| 15.01. | EQS Newswire: Gelonghui: WuXi XDC issues positive profit alert, to acquire BioDlink in bid to strengthen ADC CDMO lead | 627 | EQS Group (EN) | EQS Newswire / 15/01/2026 / 12:50 UTC+8
January 14, 2026 - WuXi XDC has issued a positive profit alert for fiscal 2025 and announced a cash tender offer for BioDlink, whose shares were suspended... ► Artikel lesen | |
| 14.01. | BIODLINK-B (01875): JOINT ANNOUNCEMENT (1) VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR ... | 2 | HKEx | ||
| 31.12.25 | BIODLINK-B (01875): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 | 2 | HKEx | ||
| 29.12.25 | BIODLINK-B (01875): TRADING HALT | 1 | HKEx | ||
| 11.11.25 | BIODLINK-B (01875): CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025 | 7 | HKEx |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,510 | -2,11 % | Prognoseschock bei Diagnostikspezialist sorgt für neue Unsicherheit: QIAGEN-Aktie unter Druck: Gewinnwarnung schürt Zweifel an Erholung | QIAGEN überrascht den Markt mit einer deutlichen Senkung der Jahresprognose für 2026. Die schwächelnde Nachfrage und zunehmende Unsicherheiten setzen den Diagnostikkonzern spürbar unter Druck.Gedämpfte... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,060 | 0,00 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| ERASCA | 9,080 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| EVOTEC | 5,005 | -2,63 % | Evotec-Aktie vor Schicksalszone: Durchbruch oder Absturz? | © Foto: fn SymbolbildEvotec hat zuletzt für Aufsehen gesorgt. Innerhalb weniger Wochen kletterte die Aktie um fast 50 Prozent nach oben, doch jetzt nähert sie sich einer Marke, die über vieles entscheiden... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 41,350 | 0,00 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| BIONTECH | 87,00 | -0,17 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,390 | 0,00 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| ADMA BIOLOGICS | 10,600 | -2,66 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| APOGEE THERAPEUTICS | 82,03 | -3,79 % | Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters | ||
| COGENT BIOSCIENCES | 35,880 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| IMMUNOVANT | 26,950 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,810 | -2,12 % | Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth | ||
| KINIKSA PHARMACEUTICALS | 53,00 | -1,58 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| DESIGN THERAPEUTICS | 15,780 | +23,18 % | Design Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates | Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,415 | -4,10 % | Dyne Therapeutics vor Quartalszahlen: Markteinführung von DMD-Therapie im Fokus |
BIODLINK INTERNATIONAL CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODLINK INTERNATIONAL CO LTD finden Sie auf Wallstreet Online.